Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent phase III trials of denosumab, a monoclonal antibody that inhibits RANKL, have demonstrated superiority over zoledronic acid in reducing skeletal morbidity in patients with metastatic bone disease. Brown and Coleman describe the emerging role of denosumab in maintaining bone health in the oncology setting and discuss the factors to consider when deciding whether to use bisphosphonates or denosumab in clinical practice.
